Peptides DB
Research-centric peptide and protocol reference hub

Orforglipron (LY-3502970) record · updated 9h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 38 studiesJump to the evidenceCompare
What is Orforglipron (LY-3502970) used for?

Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Oral

Development stage

where Orforglipron (LY-3502970) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 52 registered trials. It describes the research record, not a recommendation.

Identity
NameOrforglipron (LY-3502970)
Chain length—
Molecular weight883 Da
FormulaC48H48F2N10O5
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 137319706. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteOral
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Nov 2, 2026. How this works →
Research stats
Total studies38
Human / animal / cellular14 / 0 / 2
Highest trial phasePhase 3
Years covered2023–2026
Latest study3d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

38 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
FindingMean percentage change in bodyweight was -5.9% with orforglipron 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo (all p<0.0001).
Human2026Full text read0.80
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m<sup>2</sup> and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.
FindingAt Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.
Human2026Full text read0.80
Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment.
TakeawayNot reported in abstract.
—2026Title only0.10
Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.
TakeawayNot reported in abstract.
—2026Title only0.10
Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
TakeawayNot reported in abstract.
—2026Title only0.10
Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.
FindingPatients reduced glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%.
Human2023Full text read0.80
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
FindingHR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.
Human2026Full text read0.90
Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
TakeawayNot reported in abstract.
—2026Title only0.10
Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users
FindingMean weight change by 90 days was -3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), corresponding to a 3.55-percentage-point difference (95% CI, 1.02-6.08; P=0.007).
Human2026Full text read0.80
Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs
FindingPooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%)
review2026Full text read0.80
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.
Findingmean 7.1% to 10.6% placebo-adjusted weight reduction with orforglipron
review2026Full text read0.70
GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.
FindingHazard ratios for NAION ranged from 1.29 to 7.64.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Orforglipron (LY-3502970) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Orforglipron (LY-3502970) is discussed should be drawn from it.

Articles mentioning Orforglipron (LY-3502970)